BioVaxys Technology Corp. and SpayVac-for-Wildlife Inc. jointly announce that SpayVac has partnered with a world leader in the aquaculture space to field test single-injection, long-lasting immuno-contraceptive vaccines in farmed rainbow trout. SpayVac utilizes a patented liposome-based antigen delivery platform technology licensed from BioVaxys and has demonstrated a robust and sustained immune response in several species.

Large-scale contraception or sterilization plays a major role in the commercial aquaculture industry. As female fish mature, they put the majority of their energy into egg production, instead of muscle growth, which reduces the potential weight gain. Additionally, farm-raised fish that escape may breed with their wild counterparts and produce offspring that are less suited to surviving in the wild.

Growing reproductively contracepted or sterile fish is the most effective way to manage these challenges. In addition to fish aquaculture, SpayVac is planning to soon commercialize humane fertility control vaccines for deer, horses and other animals that are also based on the patented liposome-based delivery platform technology licensed from BioVaxys.